| Acute Leukemia |
1 |
1 |
| Acute Myeloblastic Leukemia |
0 |
0.98 |
| Chemotherapy |
0 |
0.29 |
| Biologic Therapy |
0 |
0.26 |
| Acute Promyelocytic Leukemia |
0 |
0.22 |
| Combination Chemotherapy |
0 |
0.22 |
| Cancer |
0 |
0.18 |
| Genomic Medicine |
0 |
0.18 |
| Food and Drug Administration (FDA) |
0 |
0.17 |
| Myelodysplastic Syndrome |
0 |
0.16 |
| Chronic Myelomonocytic Leukemia |
0 |
0.13 |
| Blood |
0 |
0.12 |
| Neoplasm |
0 |
0.12 |
| Targeted Cancer Therapy |
0 |
0.12 |
| Leukemia |
0 |
0.1 |
| Precision Medicine |
0 |
0.1 |
| Toxicology |
0 |
0.08 |
| Stem Cell Research and Therapy |
0 |
0.06 |
| Anthracyclines |
0 |
0.05 |
| Prognosis |
0 |
0.05 |
| Arsenic |
0 |
0.02 |
| Biomedical Technology |
0 |
0.02 |
| Clinical Research |
0 |
0.02 |
| Complementary and Alternative Medicine |
0 |
0.02 |
| Lymphoma |
0 |
0.02 |
| Multiple Myeloma |
0 |
0.02 |
| Myelosuppression |
0 |
0.02 |
| Oncogene |
0 |
0.02 |
| Pathogenesis |
0 |
0.02 |
| Quality of Life |
0 |
0.02 |
| Remission |
0 |
0.02 |
| Residual Disease |
0 |
0.02 |
| Texas |
0 |
0.02 |
| Transplantation |
0 |
0.02 |
| Tyrosine Kinase |
0 |
0.02 |